Flu Vaccine Developer Vaxart, Inc. Snags $20 Million
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Flu-fighting Vaxart Inc. raised $20 million in a Series C round. The San Francisco company, which is developing recombinant vaccines that can be taken by tablet rather than injection, did not list the investors in a Securities and Exchange Commission filing Monday. However, the company listed Richard Markham and Jan Leschly of Care Capital and Michael Finney of Finney Capital as directors. Care Capital participated in Vaxart's $12.5 million Series B financing in 2010, when Finney was Vaxart's acting CEO.
Help employers find you! Check out all the jobs and post your resume.
Flu-fighting Vaxart Inc. raised $20 million in a Series C round. The San Francisco company, which is developing recombinant vaccines that can be taken by tablet rather than injection, did not list the investors in a Securities and Exchange Commission filing Monday. However, the company listed Richard Markham and Jan Leschly of Care Capital and Michael Finney of Finney Capital as directors. Care Capital participated in Vaxart's $12.5 million Series B financing in 2010, when Finney was Vaxart's acting CEO.
Help employers find you! Check out all the jobs and post your resume.